Growth Research Overview of Global Neuropathy Pain Treatment Market Mar-2017

Global Neuropathy Pain Treatment Market 2017-2021
The Neuropathy Pain Treatment market report contains a comprehensive market and vendor landscape
in addition to a SWOT analysis of the key vendors for 2017-2021. The following companies are the key
players in the global neuropathy pain treatment market: Depomed, Eli Lilly, Endo International, and
Pfizer. Other Prominent Vendors in the market are Allodynic Therapeutics, Arbor Pharmaceuticals,
Astellas Pharma, Aurobindo Pharma, Avanir Pharmaceuticals, Biogen, CAPNIA, Centrexion Therapeutics,
Cerecor, ContraVir Pharmaceuticals, Crescita Therapeutics, DAEWOONG, Daiichi Sankyo, Dr. Reddy's
Laboratories etc.
For More Information Inquire @
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=929015
Market Trend
One trend in neuropathy pain treatment market is growing focus on emerging economies. The
increasing focus of research institutes and vendors to tap the potential treatments in emerging
economies will likely bring substantial growth opportunities. In addition, the research institutes have
issued guidelines to address the unmet needs in the treatment of pain. Vendors are also looking to tap
the potential in emerging economies.
Market Driver
One driver in neuropathy pain treatment market is presence of large patient pool. The presence of large
patient pool with neuropathic pain is expected to fuel the market growth. Neuropathic pain is
associated with various disorders such as diabetic neuropathy, chemotherapy-induced pain, shingles,
and herniated disk. There has been growing cases of the population with these disorders. Also, the
increasing individuals preferring chemotherapy for cancer treatment is fueling the cases of
chemotherapy-induced pain.
In addition, the increasing incidence of shingles is expected to drive the market growth. According to the
CDC, the incidence of shingles is approximately four per 1,000 US population annually. Further, the
disease is more prevalent in ages 60 and above. The incidence among individuals 60 years of age and
above is 10 cases per 1,000 US population annually. Overall, there are an estimated one million cases of
herpes zoster in the US annually. Such scenario will lead to an increase in adoption of neuropathic pain
drugs, which will, in turn, drive the market growth.
Market Challenge
One challenge in neuropathy pain treatment market is patent expiries hamper the growth prospects.
The patent expiry of major approved drugs is expected to impact the market adversely and is
anticipated to slow down its growth during the forecast period. Patent expiry of a drug often results in
the loss of an exclusive market for that drug, leading to a rapid decline in sales.
Purchase Report Directly @ http://www.reportsnreports.com/purchase.aspx?name=929015